Zoliflodacin: A New Antibiotic for Treating Gonorrhea

A new antibiotic, zoliflodacin, has shown promise in treating gonorrhea.
The AIDS Healthcare Foundation (AHF) has praised the promising clinical trial results for zoliflodacin.
The drug was tested in a clinical trial across 16 sites in five nations, with 930 participants.
Zoliflodacin had comparable potency in curing uncomplicated gonorrhea infections as the standard treatment, but was less effective against throat infections.

A new antibiotic, zoliflodacin, has shown promise in treating gonorrhea, the second most common sexually transmitted infection (STI) in the U.S. The drug was developed by the Global Antibiotic Research & Development Partnership and Innoviva Specialty Therapeutics. The World Health Organization estimates that there are over 82 million new gonorrhea cases globally each year.

The drug was tested in a clinical trial across 16 sites in five nations, with 930 participants. The results showed zoliflodacin had comparable potency in curing uncomplicated gonorrhea infections as the standard treatment, but was less effective against throat infections.

The AIDS Healthcare Foundation (AHF) has praised the promising clinical trial results for zoliflodacin. AHF President Michael Weinstein highlighted the importance of this development in the face of increasing antibiotic-resistant sexually transmitted infections. However, he also stressed the need for prevention over treatment to combat antimicrobial resistance. AHF has been running awareness campaigns on STI prevention and treatment in the U.S. and globally.

Confidence

50%

Doubts
  • The study does not mention if the clinical trials of zoliflodacin have been peer-reviewed.

Sources

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

New antibiotic shows promise for drug-resistant gonorrhea

NBC Washington NBC News Saturday, 04 November 2023 12:10
  • Unique Points
    • The World Health Organization estimates that there are over 82 million new gonorrhea cases globally each year.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Zoliflodacin: A Promising New Weapon Against Drug-Resistant Gonorrhea

BNN Network BNN Correspondents Saturday, 04 November 2023 04:23
  • Unique Points
    • The drug was tested in a clinical trial across 16 sites in five nations, with 930 participants.
    • The results showed zoliflodacin had comparable potency in curing uncomplicated gonorrhea infections as the standard treatment, but was less effective against throat infections.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

AHF Applauds Novel Gonorrhea Treatment

Valdosta Daily Times Business Wire Friday, 03 November 2023 21:02
  • Unique Points
    • AIDS Healthcare Foundation (AHF) has praised the promising clinical trial results for a new drug, zoliflodacin.
    • AHF President Michael Weinstein highlighted the importance of this development in the face of increasing antibiotic-resistant sexually transmitted infections.
    • However, he also stressed the need for prevention over treatment to combat antimicrobial resistance.
    • AHF has been running awareness campaigns on STI prevention and treatment in the U.S. and globally.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication